Connective Tissue Clinical Trials

58 recruitingLast updated: May 13, 2026

There are 58 actively recruiting connective tissue clinical trials across 34 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 4, Phase 3, Early Phase 1. Top locations include New York, New York, United States, New Haven, Connecticut, United States, Beijing, Beijing Municipality, China. Updated daily from ClinicalTrials.gov.


Connective Tissue Trials at a Glance

58 actively recruiting trials for connective tissue are listed on ClinicalTrialsFinder across 6 cities in 34 countries. The largest study group is Not Applicable with 17 trials, with the heaviest enrollment activity in New York, New Haven, and Beijing. Lead sponsors running connective tissue studies include Institute of Hematology & Blood Diseases Hospital, China, Hospital de Granollers, and University of Bern.

Browse connective tissue trials by phase

Treatments under study

About Connective Tissue Clinical Trials

Looking for clinical trials for Connective Tissue? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Connective Tissue trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Connective Tissue clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 58 trials

Recruiting
Phase 2

Intralesional Injection of STS in Treatment of Calcinosis

DermatomyositisSystemic Sclerosis (SSc)Mixed Connective Tissue Disease (MCTD)+1 more
Robyn T. Domsic, MD, MPH20 enrolled1 locationNCT06672822
Recruiting
Not Applicable

Pontic Site Development With or Without Fixed Partial Denture

Connective Tissue GraftKeratinized Tissue DeficiencyMucogingival Defects+1 more
Cairo University20 enrolled1 locationNCT07535060
Recruiting
Not Applicable

Early Recognition of Progressive Lung Fibrosis in Systemic Rheumatic Diseases

Interstitial Lung DiseaseConnective Tissue Diseases
Fondazione Policlinico Universitario Agostino Gemelli IRCCS200 enrolled1 locationNCT07541638
Recruiting
Not Applicable

Optimizing the Diagnostic Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-1 Trial

Fibrotic interstitial lung diseaseInterstitial Lung Disease (ILD)Idiopathic Pulmonary Fibrosis (IPF)+2 more
Hospital de Granollers92 enrolled1 locationNCT07482917
Recruiting
Not Applicable

Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial

Progressive Pulmonary FibrosisFibrotic interstitial lung diseaseInterstitial Lung Disease (ILD)+2 more
Hospital de Granollers152 enrolled1 locationNCT07486206
Recruiting
Phase 2

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

Progressive Pulmonary FibrosisInterstitial Lung DiseasePulmonary Fibrosis+7 more
Avalyn Pharma Inc.375 enrolled152 locationsNCT06329401
Recruiting
Early Phase 1

Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases

Systemic Lupus Erythematosus (SLE)Rheumatic DiseasesPediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese)+1 more
The Children's Hospital of Zhejiang University School of Medicine36 enrolled1 locationNCT07490041
Recruiting
Not Applicable

Impact of Capillaroscopy in the Investigation of Diffuse Interstitial Pneumonias

Interstitial Lung DiseaseConnective Tissue Diseases
University Hospital, Bordeaux48 enrolled1 locationNCT07283081
Recruiting
Not Applicable

Impact of Capillaroscopy on the Management of Undifferentiated Connective Tissue Disease

Undifferentiated Connective Tissue Diseases
CHU de Quebec-Universite Laval40 enrolled1 locationNCT06399822
Recruiting

Heart Institute Biobank & Registry for Adult Congenital Heart Disease and Related Disorders

Pulmonary HypertensionConnective Tissue DiseaseAdult Congenital Heart Disease+1 more
Children's Hospital Medical Center, Cincinnati5,000 enrolled1 locationNCT07477197
Recruiting
Phase 2

A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease

Non-small Cell Lung CancerNSCLCNSCLC Stage II+5 more
Memorial Sloan Kettering Cancer Center25 enrolled7 locationsNCT07323732
Recruiting
Phase 2

129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

Pulmonary Arterial HypertensionConnective Tissue DiseasesIdiopathic Pulmonary Arterial Hypertension+1 more
Bastiaan Driehuys20 enrolled1 locationNCT06104228
Recruiting
Not Applicable

A Novel Volume Stable Matrix for Gingival Recession Coverage at Teeth

Gingival RecessionConnective Tissue Defect
University of Bern60 enrolled1 locationNCT07437417
Recruiting
Not Applicable

Volumetric Dimensional Changes After Surgical Pontic Site Development Procedures With Connective Tissue Graft or Collagen Matrix

Connective Tissue GraftVolume Collagen Matrix Xenograft
University of Bern38 enrolled1 locationNCT06335628
Recruiting

Undifferentiated Connective Tissue Disease Registry

Undifferentiated Connective Tissue Disease
Hospital for Special Surgery, New York100 enrolled1 locationNCT02234388
Recruiting

Rheumatology Patient Registry and Biorepository

Rheumatoid ArthritisLyme DiseaseSarcoidosis+17 more
Yale University5,000 enrolled1 locationNCT04402086
Recruiting
Not Applicable

Developing a Nutritional Supplement to Increase Collagen Synthesis in People

ExerciseDietary SupplementsConnective Tissue
University of California, Davis20 enrolled1 locationNCT06138106
Recruiting
Not Applicable

Ganglion Resection Effectiveness Trial

Connective Tissue DiseaseWrist GanglionGanglion+2 more
Tampere University Hospital220 enrolled4 locationsNCT07162415
Recruiting
Phase 1

CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

ANCA Associated Vasculitis (AAV)SLE - Systemic Lupus ErythematosusSSc-Systemic Sclerosis+3 more
Institute of Hematology & Blood Diseases Hospital, China12 enrolled1 locationNCT07315087
Recruiting

ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

ThrombophiliaThrombosisSickle Cell Disease+10 more
American Thrombosis and Hemostasis Network3,000 enrolled71 locationsNCT04398628